Kornimate/medical-research-clean huggingface dataset:
study of endothelial dysfunction in systemic lupus and its role in heart disease

Conditions: Systemic Lupus Erythematosus

Summary: systemic lupus erythematosus is a relatively common autoimmune disease that affects mainly women.cardiovascular disease as a result of accelerated atherosclerosis is a major cause of mortality and morbidity in sle.previous research has shown that 35-40% of patients with sle have abnormalities of myocardial perfusion even when they have no coronary stenoses on coronary angiography. the reason for these frequent perfusion abnormalities in the absence of angiographically significant cad remains uncertain, but could conceivably result from endothelial dysfunction. in sle, coronary endothelial dysfunction could result from the inflammatory process involved in the sle disease itself, a finding that could explain the correlation between disease activity and the development of cad in these patients.as such endothelial dysfunction may account for accelerated atherosclerosis and cardiac perfusion defects (without angiographically significant coronary lesions). we propose to first evaluate whether endothelial dysfunction occurs in these patients and is more frequent in patients with myocardial perfusion abnormalities. endothelial function will be assessed by measuring flow-mediated brachial artery dilatation. in the 250 patients included in the study we will correlate endothelial function and myocardial perfusion abnormalities to sle disease activity, to its treatment and to the presence of cad risk factors in a subgroup of patients (estimated 5 patients) in whom it is clinically indicated, coronary angiography will be performed in order to assess the presence of significant coronary stenoses (\>50%),coronary artery reserve and coronary endothelial dysfunction. we will then attempt to reverse abnormalities in endothelial function and myocardial perfusion by therapy with an ace inhibitor(quinapril).patients with myocardial perfusion abnormalities will be randomised to receive medication a(oral quinapril or placebo) for 8 weeks, will have all baseline investigations repeated and then will switch over and receive medication b(quinapril or placebo) for a further 8 weeks followed by repeat investigations.


Eligibility criteria:
inclusion criteria: \>20 years lupus according to acr criteria patients who demonstrate abnormality on mycardial perfusion imaging are eligible for treatment arm of study - exclusion criteria: steroid dependent asthma known contraindication to dipyridamole known intolerance to or contraindication to use of ace inhibitors history of angioedema serum creatinine. 200mmol/l renal artery stenosis pregnant or breast feeding inability to perform low grade exercise presently taking ace, arb or nitrates

Keywords: endothelial dysfunction systemic lupus
msk validation study

Conditions: Proximal Junctional Kyphosis; Spino-pelvic Alignment; Thoracolumbar Spinal Fusion

Summary: spinal posture and imbalance are known to be related to increased muscle expenditure, with narrow "cone of economy" of muscle effort defining the most comfortable postures. therefore, it is hypothesized that predicting the posture of the lowest muscle effort available for a patient with a given spinal alignment and body properties will correspond to the posture the patient will most likely assume. based on established musculoskeletal models, a model application was configured to allow prediction of this optimal posture. this study aims to assess the validity of this approach and the value of using biomechanical modeling for pre-operative planning.

the objective of this study is to validate a novel method of post-operative posture prediction - a full-body biomechanical model based on an established technology and physiological reasoning. specifically, the model ability to predict postoperative global sagittal alignment, including compensatory and reciprocal changes, from pre-operative radiographic imaging and the information about planned posture correction will be evaluated. this will be realized by comparing model-predicted radiographic measures and overall balance to follow-up patient radiographs. having demonstrated model validity to predict postoperative posture will allow to use this method for simulating various "what-if" scenarios to empower surgical planning by predicting expected outcomes. this can be used to optimizing preoperative planning, which has a potential to substantially improved surgery predictability and patient outcomes. furthermore, validated model will allow scientific investigation of the principles governing human posture and biomechanics of the pathological spine. generated scientific knowledge of biomechanical factors influencing sagittal posture and surgery outcomes (e.g. number of levels fused, amount and distribution of posture correction, etc.) can lead to improvements in clinical management of spinal disorders.

Eligibility criteria:
inclusion criteria: 1. male or female patients 2. any ethnicity 3. at least 18 years of age 4. has undergone a thoracolumbar spinal fusion procedure exclusion criteria: 1. patient has had a prior spinal surgery in the thoracic and/or lumbar spine; 2. patient presents scoliosis greater or equal to 20° t4-t12 cobb angle; 3. patient has been diagnosed with idiopathic adolescent scoliosis (treated or untreated); 4. patient has other implants that obstruct the spine and/or pelvis in the lateral view; 5. patient presents any of the following complications: pseudoarthrosis, instrumentation failure, instrumentation pull-out and/or requires a revision surgery at any time following the primary surgery and prior to 3 months post-op; 6. patient is a prisoner.
safety of non-delayed weight bearing after total hip replacement with non-cemented fiber metal taper stem

Conditions: Osteoarthritis; Pain

Summary: the purpose of this study is to determine if full weight bearing following total hip replacement can speed recovery when the hip replacement in the long bone of the leg is not cemented into the bone. when cement is used, most surgeons allow full or nearly full weight bearing following hip replacement. one drawback to cementless implants has been the restriction of weight bearing for six to eight weeks after surgery, during which time patients are allowed to only put their foot flat on the floor of the operated leg without bearing weight on that leg. this study compares the effect of immediate weight bearing on the speed of recovery from hip replacement surgery in two groups of patients receiving a non-cemented total hip replacement: one group is randomly assigned to not bear weight, and the other group is randomly assigned to allowed, tolerated weight bearing from the day of surgery forward.

patients undergoing non-cemented total hip arthroplasty with a zimmer fiber metal taper stem and who meet the inclusion and exclusion criteria are offered the informed consent process. those consenting are randomized following surgery by flip of a coin into one of two groups: weight bearing as tolerated or toe touch weight bearing only. each patient is followed for two years, and is seen at 6 weeks, 3 months, 1 year and two years. questionnaires are completed including the harris hip score and the sf-36. patients complete a compliance survey to determine behavior related to their study group assignment and compliance with their study group. radiographs are obtained at each post-operative interval and subsidence is evaluated and recorded. range of motion and ambulation are assessed and recorded also.

Eligibility criteria:
inclusion criteria: * age 18 or older * english speaking * any form of hip arthritis * primary total hip arthroplasty * willing to sign informed consent exclusion criteria: * under age 18 * non-english speaking * critically ill patients * people who are unable to follow-up appropriately due to travel concerns or mental illness. * revision total hip arthroplasty * trochanteric osteotomy * intra-operative fracture * prisoners * not willing to sign informed consent

Keywords: weight-bearing total hip replacement non-cemented randomized fiber-metal-taper-stem hip osteoarthritis
pain following one-visit versus two-visit root canal of necrotic teeth using protaper next

Conditions: Tooth, Nonvital

Summary: to evaluate the incidence and severity of postoperative pain after root canal therapy of necrotic teeth in one appointment versus two appointments using protaper next instrument.

the key to endodontic success was described as the debridement and neutralization of any tissue, bacteria, or inflammatory products within the root canal system. endodontic treatment used to take multiple visits to complete, with one of the main reasons for this being that it required a considerable amount of time to complete the treatment. the single-visit treatment was bought back in the 1950s by ferranti, who advocated the use of diathermy for pulpal disinfection and hydrogen peroxide for irrigation. the use of contemporary endodontic techniques and equipment, such as use of rubber dam, magnifying devices, electronic apex locators, engine-driven rotary nickel titanium files, and so forth, not only increases the success rate of endodontic treatment but also, shortens the time needed for the treatment. endodontic treatment may therefore be completed in a single visit. it is generally agreed upon that the prepared canals can never be sterile before obturation, no matter how potent the antibacterial irrigants or intracanal medications are. there are currently two measures to reduce bacterial persistence and reinfection in the canals. we can either dress the canals with antibacterial agents in multiple visits or immediately obturate the canals, to reduce the space for bacterial colonization, in a single-visit approach. calcium hydroxide is the most commonly used intracanal medicament, however its efficacy towards enterococcus faecalis is questionable.

Eligibility criteria:
inclusion criteria: * medically free patients. * patient's age above 18 years old. * teeth diagnosed clinically with necrosis. * positive patient's acceptance for participation in the study. * sex includes both male and female. * patients who can understand visual analogue scale. * patients able to sign informed consent. exclusion criteria: * pregnancy or lactation. * medically compromised patients. * patient with multiple teeth that required treatment in the same quadrant to eliminate the possibility of pain referral.

Keywords: necrotic teeth single visit multiple visits protaper next
study of fruquintinib in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: fruquintinib administered at 5mg once daily in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced colorectal cancer (crc) in phase ib study. this study is aimed to evaluate the efficacy and safety of fruquintinib in the treatment of patients with metastatic crc who have progressed after metastatic crc second line or above standard chemotherapy.

this is a randomized, double-blind, placebo-controlled, multicenter phase ii clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (bsc) versus placebo plus bsc in patients with metastatic colorectal cancer who have progressed after second-line or above standard chemotherapy. after checking eligibility criteria, subjects will be randomized into fruquintinib plus bsc group (treatment group) or placebo plus bsc group (control group) in a ration of 2:1. primary efficacy endpoint: progression free survival (pfs) (according to recist version 1.1). secondary efficacy endpoints: objective response rate (orr), disease control rate (dcr), overall survival (os). safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (aes) and categorized by severity in accordance with the nci common terminology criteria for adverse events (ctc ae) version 4.0.

Eligibility criteria:
inclusion criteria: * ≥ 18 and ≤ 75 years of age , with ≥ 40 kg * histological or cytological confirmed metastatic colorectal cancer * eastern cooperative oncology group (ecog) performance status of 0-1 * failed 2 or more lines of chemotherapy * adequate hepatic, renal, heart, and hematologic functions * at least one measurable lesion (larger than 10 mm in diameter by spiral ct scan) * signed and dated informed consent. * willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure exclusion criteria: * pregnant or lactating women * any factors that influence the usage of oral administration * central nervous system (cns) metastasis * one of the following conditions: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure * abuse of alcohol or drugs * less than 4 weeks from the last clinical trial - previous treatment with vegfr inhibition * disability of serious uncontrolled intercurrence infection * proteinuria ≥ 2+ (1.0g/24hr) * evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness * history of artery/venous thromboembolic events in 12 months, such as cerebral vascular accident (including transient ischemic attack) etc. * history of acute myocardial infarction, acute coronary syndrome or coronary artery bypass graft (cabg) in 6 months * bone fracture or wounds that was not cured for a long time * coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

Keywords: colorectal cancer fruquintinib 013
molecular autopsy study

Conditions: Sudden Unexplained Death

Summary: this study seeks to incorporate genetic testing into the postmortem examination of cases of sudden unexplained death.

this study seeks to incorporate genetic testing into the postmortem examination of cases of sudden unexplained death, initially in san diego county with plans to expand nationally and internationally as funding allows. genetic testing of the index subjects and their parents (or other biological family members if parents are not available) will be assessed for potential heritable causes of sudden death. by combining the wide catchment base of the san diego medical examiner's office, sequencing expertise of sd-based collaborators, computing power of the san diego supercomputer center and in-house and external genomic analytics, the scripps translational science institute aims to provide a more complete characterization and understanding of the genetic causes of sudden death. ultimately, findings from this study will be utilized to identify previously unrecognized mechanism of sudden death allowing for the development of preventative screening programs and potentially life-saving interventions.

Eligibility criteria:
inclusion criteria: * index case age between birth - 45 years * clinical presentation of sudden / unexplained death (believed to be cardiac in nature or secondary to a massive unprovoked pulmonary embolism with no prior diagnosis of prothrombotic disease) exclusion criteria: * premature death secondary to murder, suicide or external causal event * premature death thought secondary to known chronic comorbid medical condition * premature death thought secondary to end-organ failure (kidney, liver, lung) other than heart * previously diagnosed with hypertrophic cardiomyopathy (hcm) * prior myocardial infarction (regardless of stenting or bypass) * prior cerebrovascular accident (stroke or tia) * history of open heart surgery (for any reason) * history of severe, untreated hypertensive heart disease * history of illicit drug use * history of heavy alcohol abuse * history of severe pulmonary disease * history of morbid obesity

Keywords: sudden unexplained death
open-label extension of lockcyst trial

Conditions: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney; Autosomal Dominant

Summary: positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. these two patients had complicated polycystic livers and no other therapeutic options were available. patients who participated in lockcyst trial are able to benefit from active treatment. participants will be actively treated for 24 weeks.

van keimpema l, de man ra, drenth jp. somatostatin analogues reduce liver volume in polycystic liver disease. gut 2008 september;57(9):1338-9.

Eligibility criteria:
inclusion criteria: * participated in the lockcyst trial * 18 yrs-of age * multiple cysts \> 20 * cooperating patient * is willing and able to comply with the study drug regimen and all other study requirements. * willingness to give written informed consent exclusion criteria: * use of oral anticonceptives or estrogen suppletion * females who are pregnant or breast-feeding * history or other evidence of chronic pulmonary disease associated with functional limitation * history of severe cardiac disease (eg, nyha functional class iii or iv, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). in addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled. * history or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * symptomatic gallstones (lanreotide decreases gall bladder volume) * renal failure requiring hemodialysis
acetazolamide in patients with acute heart failure

Conditions: Heart Failure; Acute Heart Failure

Summary: introduction: recent studies have suggested that the use of acetazolamide may assist in the vol- ume management of patients with decompensated heart failure (hf). however, prospective and randomized comparison in patients with hf and optimized diuretic therapy has not been described. objective: the aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated hf. methodology: for this, a unicentric, randomized, double blind and prospective study will be performed in a comparative manner. hospital data (test results, medical outcomes, drug dose, complications) of patients will be analyzed for safety and effectiveness. expected results: the use of acetazolamide as an adjuvant treatment is superior to the standard strategy for volume control in patients with decompensated hf.


Eligibility criteria:
inclusion criteria: * adult men and women aged\> 18 years. * patients with lvef ≤ 40% documented on echocardiography * bnp\> 500 pg / ml * signed consent form. exclusion criteria: * pregnancy * copd * hepatical cirrhosis * known allergy to acetazolamide * 2nd or 3rd degree atrioventricular block. * sbp \<90 mmhg or need for vasopressor / inotropic use. * body mass index greater than 40 kg / m2. * acute coronary syndrome. * orotracheal intubation. * presence of significant pericardial effusion. * left ventricular outflow tract obstruction. * serum creatinine\> 5.0 mg / dl, creatinine clearance \<10 ml / min or hemodialysis. * presence of 2 or more clinical / laboratory / radiological criteria of infection defined by: * fever * leukocyte\> 12,000 / mm3 or\> 10% of young forms, * disuria * productive cough * bacteremia * inflammatory / infectious skin lesions * abdominal pain with signs of peritonitis * radiological image of pneumonia.
lucy: a study for the treatment of non-small cell lung cancer (nsclc) in patients previously treated with chemotherapy

Conditions: Lung Cancer; Cancer of Lung; Cancer of the Lung; Non-Small Cell Lung Carcinoma; Carcinoma, Non-Small Cell Lung

Summary: a study for the treatment of non-small cell lung cancer (nsclc) in patients previously treated with chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed non-small cell lung cancer. * prior chemotherapy regimen(s) for lung cancer exclusion criteria: * history of other malignancy in the last 5 years * major surgery within the past 21 days

Keywords: treatment efficacy treatment effectiveness disease management treatment safety
hydrolyzed collagen combined with djulis and green caviar improve skin condition

Conditions: Skin Condition

Summary: collagen combined with djulis and green caviar improve skin condition

using collagen drinks combined fish collagen with djulis, and green caviar to improve skin condition.

Eligibility criteria:
inclusion criteria: 1. dry skin 2. rough skin 3. large pores 4. dark yellow complexion 5. sagging skin exclusion criteria: 1. skin disorders 2. liver diseases 3. kidney diseases 4. allergy to cosmetics, drugs, or foods 5. pregnant and lactating women 6. people who had any cosmetic procedures before 4 weeks of the study 7. area of facial spot over 3 cm2 8. vegan 9. people who took collagen supplements in the past 3 months.
open label extension study of romiplostim (amg 531) in thrombocytopenic patients with immune (idiopathic) thrombocytopenic purpura (itp)

Conditions: Thrombocytopenia; Idiopathic Thrombocytopenic Purpura

Summary: the purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with itp, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. participants must have previously completed a romiplostim itp study.


Eligibility criteria:
inclusion criteria: * must have previously completed a romiplostim itp study * platelet count ≤ 50 x 10 \^9/l * written informed consent exclusion criteria: * bone marrow stem cell disorder or new active malignancies diagnosed since enrollment in the previous romiplostim itp study * received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study * currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous romiplostim itp study), or subject is receiving other investigational agent(s) other than romiplostim * not using adequate contraceptive precautions * not available for follow-up assessments * has any kind of disorder that compromises the ability of the participant to give informed consent and does not have a legally-acceptable representative and/or is unable to comply with study procedures.

Keywords: immune (idiopathic) thrombocytopenic purpura (itp) thrombocytopenic